Australia and New Zealand Dialysis and Transplant Registry

The Australia and New Zealand Dialysis and Transplant Registry is a regional observational data system whose published analyses illuminate the long-term consequences of hepatitis C virus infection across dialysis and kidney transplantation. Its importance lies in scale and duration: registry cohorts showed that anti-HCV positivity was associated with increased all-cause mortality and that, among kidney recipients, poorer graft survival emerged most clearly with extended follow-up, when liver disease and HCV-related renal injury could become clinically consequential.

Scope and Epidemiological Role

The registry’s evidence belongs to a broader shift in the understanding of hepatitis C virus infection in chronic kidney disease. HCV is not confined to the liver; it can produce renal, autoimmune, and other extrahepatic disease, and it became an important subject for nephrology, dialysis, and transplantation guidance. In dialysis populations, infection was initially recognized as common during the 1990s, when transfusion exposure remained substantial and nosocomial transmission within hemodialysis units was also suspected. As blood-donor screening improved and erythropoiesis-stimulating agents reduced the need for transfusion, the relative importance of transfusion-related transmission declined, leaving infection-control practices in dialysis units as a central concern.

The registry provided a population-level counterweight to smaller single-center studies. Its cohorts included patients receiving dialysis as well as kidney-transplant recipients, allowing investigators to examine outcomes over years rather than treating anti-HCV status as an isolated laboratory finding. This was particularly valuable because HCV-related liver injury may develop slowly after transplantation, so studies with short follow-up could fail to detect differences that became evident later.

Evidence on Mortality in Dialysis

A registry analysis of 23,046 patients from Australia and New Zealand found an independent association between anti-HCV-positive serologic status and all-cause mortality during ten years of follow-up. The reported hazard ratio was 1.25, with a 95% confidence interval of 1.07–1.46 and a p value of 0.004. The result persisted after adjustment, indicating that the association was not simply explained by the other measured characteristics of the dialysis population.

The pattern of causes of death was clinically distinctive. Hepatic failure was more common among anti-HCV-positive patients, with an adjusted hazard ratio of 5.79, although it remained an infrequent event at 0.34 deaths per 100 patients per year. Among malignancy-related deaths, primary liver cancer accounted for one of nine deaths in the anti-HCV-positive group, compared with twelve of 583 malignancy deaths in the anti-HCV-negative group. The investigators therefore suggested that many infected dialysis patients might die before the very late complications of HCV-related liver disease, such as cirrhosis or hepatocellular carcinoma, fully develop.

The registry findings aligned with evidence from other Asia-Pacific cohorts. In a separate analysis, anti-HCV antibody status predicted all-cause mortality in 21,487 Australian and New Zealand patients, both when antibody positivity was present at baseline and when it was acquired during dialysis. The baseline association had an adjusted hazard ratio of 1.29, while seroconversion during dialysis had an adjusted hazard ratio of 1.27. These results strengthened the interpretation that HCV status mattered across the dialysis course, not merely at the moment of enrollment.

Findings in Kidney Transplantation

The registry also documented an adverse long-term transplant profile for HCV-positive recipients. In its analysis of graft survival, five-year graft survival was worse in the anti-HCV-positive cohort, with an adjusted hazard ratio of 1.71 for graft failure and a p value below 0.001. The causes of graft loss were not distributed randomly: failures among infected recipients were significantly more likely to be attributed to glomerulonephritis and chronic allograft nephropathy, with adjusted hazard ratios of 2.71 and 1.87, respectively.

These observations fit the wider evidence base while preserving its important qualifications. A meta-analysis of eight clinical trials involving 6,365 patients found that HCV infection was associated with increased mortality after kidney transplantation, with a relative risk of 1.79, and with graft failure, with a relative risk of 1.56. Increased mortality was partly related to liver-related death, while increased graft loss was associated in part with HCV-related renal disease. The registry therefore helped make visible a combined burden: HCV could threaten the recipient through progressive liver disease and the allograft through glomerulonephritis or chronic allograft injury.

The interpretation was not uniform across every study. Some investigations with shorter follow-up found no significant difference between HCV-positive and HCV-negative recipients, and some studies reported comparable graft outcomes. Differences in study design, duration of observation, baseline liver histology, comorbidities, and immunosuppressive regimens could all influence the result. The registry’s contribution was especially persuasive because its larger population and longer observation captured the delayed adverse outcomes that short studies could miss.

Clinical and Institutional Significance

The registry’s findings did not imply that an HCV-infected patient with end-stage renal disease should remain on dialysis instead of receiving a kidney transplant. Comparative studies showed that transplantation still conferred a survival advantage over continued waiting-list status for HCV-infected candidates, provided that advanced liver injury was excluded during pretransplant evaluation. The registry’s evidence instead sharpened the conditions under which transplantation should proceed: candidates require screening for anti-HCV antibodies and active viremia, assessment of liver disease, and continuing surveillance while they remain on the waiting list.

Its data also exposed why anti-HCV antibody status cannot be treated as a complete definition of active disease. Diagnosis requires both antibody detection and detectable HCV RNA to establish chronic active infection; antibody positivity may reflect current or resolved infection. Likewise, transplant outcomes depend on the severity and duration of infection, preexisting liver damage, and the immunosuppression used after transplantation. The registry’s associations therefore function as risk signals for clinical planning rather than as proof that every individual with an anti-HCV-positive result will experience the same course.

By linking a large regional population to outcomes across dialysis and transplantation, the Australia and New Zealand Dialysis and Transplant Registry turned scattered clinical observations into a durable epidemiological picture. It showed that the consequences of HCV may remain understated when follow-up is brief, that mortality and graft failure are distinct but connected endpoints, and that the apparent price of infection is shaped by both hepatic disease and renal-allograft complications. Its work helped place HCV status within the practical chain of screening, liver staging, transplant selection, post-transplant monitoring, and long-term outcome assessment.